A breakthrough blood test that helps personalise treatment for rheumatoid arthritis (RA) is being introduced to patients in Colombia, Panama, and Costa Rica.

Developed by US-based precision immunology company Scipher Medicine, PrismRA identifies patients who are unlikely to respond to TNFi therapy, the world’s most commonly prescribed class of RA drugs. By ruling out ineffective treatments, the test enables doctors to move patients onto alternative therapies earlier, avoiding unnecessary side effects and delays in care.

“Partnering with Grupo Amarey allows us to bring PrismRA to patients who can benefit most,” said Reg Seeto, CEO of Scipher Medicine. “Their deep understanding of the local healthcare system and commitment to innovation make them an ideal partner.”

The collaboration with Grupo Amarey, a leading healthcare distributor in the region, marks Scipher Medicine’s first international expansion. For patients, it promises more personalised care pathways and improved outcomes in a disease that affects millions worldwide.

UK and Ireland law firm Browne Jacobson advised Scipher Medicine on the cross-border partnership, supporting areas from commercial agreements to regulatory and data considerations. “We are proud to have supported the in-house legal team at Scipher Medicine on this deal, which allows them to deliver their precision medicine technology to patients in Latin America,” said Clare Auty, Partner and Head of Independent Health and Social Care. “It’s a strong example of how we work with international clients who are tackling some of society’s biggest challenges, particularly in improving health outcomes.”

With PrismRA now entering new markets, Scipher Medicine is extending the reach of precision diagnostics that have the potential to reshape how chronic autoimmune diseases are treated.